408 related articles for article (PubMed ID: 28376230)
21. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
22. Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.
Mills CC; Kolb EA; Sampson VB
Cancer Res; 2017 Dec; 77(23):6489-6498. PubMed ID: 29097609
[TBL] [Abstract][Full Text] [Related]
23. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
24. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
[TBL] [Abstract][Full Text] [Related]
25. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.
Cortés J; Im SA; Holgado E; Perez-Garcia JM; Schmid P; Chavez-MacGregor M
Cancer Treat Rev; 2017 Dec; 61():53-60. PubMed ID: 29100169
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
27. Perspectives on research activity in the USA on Cancer Precision Medicine.
Bando H; Takebe N
Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Vidula N; Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
30. Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.
Shohdy KS; Vlachostergios PJ; Abdel-Malek RR; Faltas BM
Expert Opin Ther Targets; 2019 Feb; 23(2):83-86. PubMed ID: 30558440
[No Abstract] [Full Text] [Related]
31. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.
Turner NC; Neven P; Loibl S; Andre F
Lancet; 2017 Jun; 389(10087):2403-2414. PubMed ID: 27939057
[TBL] [Abstract][Full Text] [Related]
32. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology.
Lorusso PM; Eder JP
Expert Opin Investig Drugs; 2008 Jul; 17(7):1013-28. PubMed ID: 18549338
[TBL] [Abstract][Full Text] [Related]
34. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
35. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
36. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
37. Developing novel strategies to target B-cell malignancies.
Fowler N; Oki Y
Am Soc Clin Oncol Educ Book; 2013; ():366-72. PubMed ID: 23714549
[TBL] [Abstract][Full Text] [Related]
38. New targets and new mechanisms in lung cancer.
Carrizosa DR; Mileham KF; Haggstrom DE
Oncology (Williston Park); 2013 May; 27(5):396-404. PubMed ID: 25184262
[TBL] [Abstract][Full Text] [Related]
39. New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.
Zajac M; Muszalska I; Jelinska A
Curr Med Chem; 2016; 23(37):4176-4220. PubMed ID: 27528054
[TBL] [Abstract][Full Text] [Related]
40. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
